Semaphorin 3F is elevated in serum of heart failure patients and inhibits cardiac angiogenesis via the VEGF/Akt/eNOS pathway

Semaphorin 3F is elevated in serum of heart failure patients and inhibits cardiac angiogenesis via the VEGF/Akt/eNOS pathway

Left ventricular (LV) remodeling in heart failure (HF) is associated with vascular rarefaction and impaired angiogenesis. The inhibition of vascular endothelial growth factor (VEGF)-mediated angiogenesis is a key feature in the pathophysiology of HF. Semaphorin (Sema) 3F is a known inhibitor of VEGF...

Full description

Saved in:
Bibliographic Details
Main Authors: Diana Petrova, Miki Weberbauer, Stephanie Reichert, Stephanie Scheid, Jennifer Esser, Katrin Fink, Daniel Duerschmied, Martin Moser, Thomas Helbing
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:Journal of Molecular and Cellular Cardiology Plus
Subjects:
Heart failure
Remodeling
Microvascular rarefaction
Angiogenesis
Semaphorin 3F
VEGF
Online Access:http://www.sciencedirect.com/science/article/pii/S2772976125001898
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2772976125001898

Similar Items